[HTML][HTML] Transdermal fentanyl versussustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life
S Ahmedzai, D Brooks… - Journal of pain and …, 1997 - Elsevier
Cancer patients requiring strong opioid analgesia (n= 202; mean age, 61.5 years; range, 18–
89 years; 55% men) were recruited from 38 United Kingdom palliative care centers into a …
89 years; 55% men) were recruited from 38 United Kingdom palliative care centers into a …
Transdermal fentanyl versussustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life
S Ahmedzai, D Brooks - Journal of Pain and Symptom …, 1997 - jpsmjournal.com
Cancer patients requiring strong opioid analgesia (n= 202; mean age, 61.5 years; range, 18–
89 years; 55% men) were recruited from 38 United Kingdom palliative care centers into a …
89 years; 55% men) were recruited from 38 United Kingdom palliative care centers into a …
Transdermal fentanyl versussustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life
S Ahmedzai, D Brooks - Journal of Pain and Symptom Management, 1997 - infona.pl
Cancer patients requiring strong opioid analgesia (n= 202; mean age, 61.5 years; range, 18–
89 years; 55% men) were recruited from 38 United Kingdom palliative care centers into a …
89 years; 55% men) were recruited from 38 United Kingdom palliative care centers into a …
Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.
S Ahmedzai, D Brooks - Journal of Pain and Symptom Management, 1997 - europepmc.org
Cancer patients requiring strong opioid analgesia (n= 202; mean age, 61.5 years; range, 18-
89 years; 55% men) were recruited from 38 United Kingdom palliative care centers into a …
89 years; 55% men) were recruited from 38 United Kingdom palliative care centers into a …
Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group
S Ahmedzai, D Brooks - Journal of pain and symptom …, 1997 - pubmed.ncbi.nlm.nih.gov
Cancer patients requiring strong opioid analgesia (n= 202; mean age, 61.5 years; range, 18-
89 years; 55% men) were recruited from 38 United Kingdom palliative care centers into a …
89 years; 55% men) were recruited from 38 United Kingdom palliative care centers into a …
[引用][C] Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life
S AHMEDZAI, D BROOKS - Journal of pain and symptom …, 1997 - pascal-francis.inist.fr
Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference,
efficacy, and quality of life CNRS Inist Pascal-Francis CNRS Pascal and Francis …
efficacy, and quality of life CNRS Inist Pascal-Francis CNRS Pascal and Francis …
[引用][C] Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS Fentanyl Comparative Trial Group
S AHMEDZAI - J Pain Symptom Manage, 1997 - cir.nii.ac.jp
Transdermal fentanyl versus sustained-release oral morphine in cancer pain : preference,
efficacy, and quality of life. The TTS Fentanyl Comparative Trial Group | CiNii Research CiNii …
efficacy, and quality of life. The TTS Fentanyl Comparative Trial Group | CiNii Research CiNii …
[引用][C] Transdermal fentanyl versussustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life
S Ahmedzai, D Brooks - Journal of Pain and Symptom Management, 1997 - cir.nii.ac.jp
Transdermal fentanyl versussustained-release oral morphine in cancer pain: Preference,
efficacy, and quality of life | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
efficacy, and quality of life | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …